All in on novel target GSK-3β, Actuate Therapeutics raises $21M+ to bankroll ambitious PhI/II
As Actuate Therapeutics ramps up recruitment for what it calls a “groundbreaking” Phase I/II involving refractory blood cancers and solid tumors, the biotech has secured …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.